Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Announces UNSW Combine on Stroke Project

- Noxopharm drug identified as potential brain/spinal cord injury preventative

- First-in-class drug to hasten rehabilitation from brain and spinal cord injury

- Made possible because of NOX66 drug delivery platform

- UNSW assisting in pre-clinical studies.

Sydney, 15 March 2017: Noxopharm Ltd (ASX:NOX) today unveils the first of its non-oncology drug pipeline, having entered into a research agreement with the University of New South Wales (UNSW) to develop a unique and highly sought preventative treatment for damage to the central nervous system. This includes stroke and spinal injury, and potentially a wide range of neurodegenerative diseases.

For further information please download PDF attached: 
Download this document